Skip to main content
Top
Published in: Rheumatology International 10/2016

01-10-2016 | Food for Thought

Fatigue, pain and patient global assessment responses to biological treatment are unpredictable, and poorly inter-connected in individual rheumatoid arthritis patients followed in the daily clinic

Authors: Ole Rintek Madsen, Eva Marie Egsmose

Published in: Rheumatology International | Issue 10/2016

Login to get access

Abstract

The objective of the study was to investigate relations on group level and agreements on the individual patient level between changes in fatigue, pain and patient global assessment (PaGl) assessed on visual analogue scales (VAS) in patients with rheumatoid arthritis (RA) after initiating or switching biological treatment. Associations with other disease measures were also examined. Traditional disease activity data on 177 patients with RA registered before and after 6-month treatment were extracted from the Danish DANBIO registry. Associations were examined using multiple regression analysis. Agreement between the VAS score changes (∆) was expressed as the bias (mean difference) and the 95 % lower and upper limits of agreement (LoA). All disease measures improved significantly. ∆fatigue, ∆pain and ∆PaGl were independently associated with each other (r partial range 0.38–0.81, p < 0.0001), but not to a significant degree with changes in other measures. Lower and upper LoA [bias] for ∆fatigue versus ∆pain was −44.0 and 51.8 [3.9], for ∆fatigue versus ∆PaGl −38.2 and 52.4 [4.2], and for ∆PaGl versus ∆pain −34.3 and 34.3 [0.0]. ∆fatigue, ∆pain and ∆PaGl were independently but weakly predicted by their own baseline values (r partial range −0.30 to −0.46, p < 0.0001). In conclusion, changes in fatigue, pain and PaGl were independently associated and nearly identical on group level but agreements were poor in individual patients. The changes were poorly explained by other potential predictor variables and by baseline values. The results expose the unpredictable nature of patient-reported VAS scores in individual patients with RA.
Literature
1.
go back to reference Alamanos Y, Voulgari PV, Drosos AA (2006) Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 36:182–188CrossRefPubMed Alamanos Y, Voulgari PV, Drosos AA (2006) Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 36:182–188CrossRefPubMed
2.
go back to reference Grøn KL, Ornbjerg LM, Hetland ML, Aslam F, Khan NA, Jacobs JW et al (2014) The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Clin Exp Rheumatol 32:869–877PubMed Grøn KL, Ornbjerg LM, Hetland ML, Aslam F, Khan NA, Jacobs JW et al (2014) The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Clin Exp Rheumatol 32:869–877PubMed
3.
go back to reference Van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P (2010) Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology (Oxford) 49:1294–1302CrossRef Van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P (2010) Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology (Oxford) 49:1294–1302CrossRef
4.
go back to reference Hewlett S (2011) Fatigue in rheumatoid arthritis: time for a conceptual model. An under-acknowledged patient concern requires a new approach. Rheumatology 50:1004–1006CrossRefPubMed Hewlett S (2011) Fatigue in rheumatoid arthritis: time for a conceptual model. An under-acknowledged patient concern requires a new approach. Rheumatology 50:1004–1006CrossRefPubMed
5.
go back to reference Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL (2006) Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology 45:885–889CrossRefPubMed Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL (2006) Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology 45:885–889CrossRefPubMed
6.
go back to reference Thyberg I, Dahlstrom O, Thyberg M (2009) Factors related to fatigue in women and men with early rheumatoid arthritis: the Swedish TIRA study. J Rehabil Med 41:904–912CrossRefPubMed Thyberg I, Dahlstrom O, Thyberg M (2009) Factors related to fatigue in women and men with early rheumatoid arthritis: the Swedish TIRA study. J Rehabil Med 41:904–912CrossRefPubMed
7.
go back to reference Huyser BA, Parker JC, Thoreson R, Smarr KL, Johnson JC, Hoffman R (1998) Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis Rheum 41:2230–2237CrossRefPubMed Huyser BA, Parker JC, Thoreson R, Smarr KL, Johnson JC, Hoffman R (1998) Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis Rheum 41:2230–2237CrossRefPubMed
8.
go back to reference Egsmose EL, Madsen OR (2015) Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis. Clin Rheumatol 34:1187–1194CrossRefPubMed Egsmose EL, Madsen OR (2015) Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis. Clin Rheumatol 34:1187–1194CrossRefPubMed
9.
go back to reference Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL (1993) Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 42:93–99CrossRefPubMed Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL (1993) Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 42:93–99CrossRefPubMed
10.
go back to reference Studenic P, Radner H, Smolen JS, Aletaha D (2012) Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 64:2814–2823CrossRefPubMed Studenic P, Radner H, Smolen JS, Aletaha D (2012) Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 64:2814–2823CrossRefPubMed
11.
go back to reference Kalyoncu U, Dougados M, Daures JP, Gossec L (2009) Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 68:183–190CrossRefPubMed Kalyoncu U, Dougados M, Daures JP, Gossec L (2009) Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 68:183–190CrossRefPubMed
12.
go back to reference Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M et al (2005) Incorporating the patient perspective into outcome assessment in rheumatoid arthritis—progress at OMERACT 7. J Rheumatol 32:2250–2256PubMed Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M et al (2005) Incorporating the patient perspective into outcome assessment in rheumatoid arthritis—progress at OMERACT 7. J Rheumatol 32:2250–2256PubMed
13.
go back to reference Pincus T, Amara I, Segurado OG, Bergman M, Koch GG (2008) Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol 35:201–205CrossRefPubMed Pincus T, Amara I, Segurado OG, Bergman M, Koch GG (2008) Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol 35:201–205CrossRefPubMed
14.
go back to reference Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P (2010) Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford) 49:1900–1910CrossRef Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P (2010) Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford) 49:1900–1910CrossRef
15.
go back to reference Yazici Y, Bergman M, Pincus T (2008) Time to score quantitative rheumatoid arthritis measures: 28-joint count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol 35:603–609PubMed Yazici Y, Bergman M, Pincus T (2008) Time to score quantitative rheumatoid arthritis measures: 28-joint count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol 35:603–609PubMed
16.
17.
go back to reference Sanderson T, Morris M, Calnan M, Richards P, Hewlett S (2010) Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res (Hoboken) 62:647–656CrossRef Sanderson T, Morris M, Calnan M, Richards P, Hewlett S (2010) Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res (Hoboken) 62:647–656CrossRef
18.
go back to reference Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M et al (2007) Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 34:1174–1177PubMed Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M et al (2007) Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 34:1174–1177PubMed
19.
go back to reference Kirwan JR, Hewlett S (2007) Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis. J Rheumatol 34:1171–1173PubMed Kirwan JR, Hewlett S (2007) Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis. J Rheumatol 34:1171–1173PubMed
20.
go back to reference Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B et al (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36:729–740CrossRefPubMed Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B et al (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36:729–740CrossRefPubMed
21.
go back to reference Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C et al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 59:1371–1377CrossRefPubMed Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C et al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 59:1371–1377CrossRefPubMed
22.
go back to reference Khan NA, Spencer HJ, Abda EA, Alten R, Pohl C, Ancuta C et al (2012) Patient’s global assessment of disease activity and patient’s assessment of general health for rheumatoid arthritis activity assessment: Are they equivalent? Ann Rheum Dis 71:1942–1949CrossRefPubMedPubMedCentral Khan NA, Spencer HJ, Abda EA, Alten R, Pohl C, Ancuta C et al (2012) Patient’s global assessment of disease activity and patient’s assessment of general health for rheumatoid arthritis activity assessment: Are they equivalent? Ann Rheum Dis 71:1942–1949CrossRefPubMedPubMedCentral
23.
go back to reference Amaya-Amaya J, Botello-Corzo D, Calixto OJ, Calderón-Rojas R, Domínguez AM, Cruz-Tapias P et al (2012) Usefulness of patients-reported outcomes in rheumatoid arthritis focus group. Arthritis 2012:935187CrossRefPubMedPubMedCentral Amaya-Amaya J, Botello-Corzo D, Calixto OJ, Calderón-Rojas R, Domínguez AM, Cruz-Tapias P et al (2012) Usefulness of patients-reported outcomes in rheumatoid arthritis focus group. Arthritis 2012:935187CrossRefPubMedPubMedCentral
24.
go back to reference Nikolaus S, Bode C, Taal E, van de Laar MA (2013) Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 65:1128–1146CrossRef Nikolaus S, Bode C, Taal E, van de Laar MA (2013) Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 65:1128–1146CrossRef
25.
go back to reference Ward MM, Guthrie LC, Alba MI (2015) Measures of arthritis activity associated with patient-reported improvement in rheumatoid arthritis when assessed prospectively versus retrospectively. Arthritis Care Res (Hoboken) 67:776–781CrossRef Ward MM, Guthrie LC, Alba MI (2015) Measures of arthritis activity associated with patient-reported improvement in rheumatoid arthritis when assessed prospectively versus retrospectively. Arthritis Care Res (Hoboken) 67:776–781CrossRef
26.
go back to reference Minnock P, McKee G, Bresnihan B, FitzGerald O, Veale DJ (2014) How much is fatigue explained by standard clinical characteristics of disease activity in patients with inflammatory arthritis? A longitudinal study. Arthritis Care Res (Hoboken) 66:1597–1603CrossRef Minnock P, McKee G, Bresnihan B, FitzGerald O, Veale DJ (2014) How much is fatigue explained by standard clinical characteristics of disease activity in patients with inflammatory arthritis? A longitudinal study. Arthritis Care Res (Hoboken) 66:1597–1603CrossRef
27.
go back to reference Druce KL, Jones GT, Macfarlane GJ, Basu N (2015) Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 54:964–971CrossRef Druce KL, Jones GT, Macfarlane GJ, Basu N (2015) Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 54:964–971CrossRef
28.
go back to reference Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab. Arthritis Rheum 62:22–32CrossRefPubMed Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab. Arthritis Rheum 62:22–32CrossRefPubMed
29.
go back to reference Hetland ML (2011) DANBIO—powerful research database and electronic patient record. Rheumatology (Oxford) 50:69–77CrossRef Hetland ML (2011) DANBIO—powerful research database and electronic patient record. Rheumatology (Oxford) 50:69–77CrossRef
30.
go back to reference Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23(Suppl 39):S100–S108PubMed Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23(Suppl 39):S100–S108PubMed
31.
go back to reference Madsen OR (2013) Agreement between the DAS28-CRP assessed with 3 and 4 variables in patients with rheumatoid arthritis treated with biological agents in the daily clinic. J Rheumatol 40:379–385CrossRefPubMed Madsen OR (2013) Agreement between the DAS28-CRP assessed with 3 and 4 variables in patients with rheumatoid arthritis treated with biological agents in the daily clinic. J Rheumatol 40:379–385CrossRefPubMed
32.
go back to reference Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307–310CrossRefPubMed Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307–310CrossRefPubMed
33.
go back to reference Hallahan M, Rosenthal R (1996) Statistical power: concepts, procedures, and applications. Behav Res Ther 34:489–499CrossRefPubMed Hallahan M, Rosenthal R (1996) Statistical power: concepts, procedures, and applications. Behav Res Ther 34:489–499CrossRefPubMed
34.
go back to reference Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR et al (2006) Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 65:1373–1378CrossRefPubMedPubMedCentral Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR et al (2006) Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 65:1373–1378CrossRefPubMedPubMedCentral
35.
go back to reference Wolfe F (2004) Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 31:1896–1902PubMed Wolfe F (2004) Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 31:1896–1902PubMed
36.
go back to reference Wells G, Li T, Maxwell L, Maclean R, Tugwell P (2008) Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 67:260–265CrossRefPubMed Wells G, Li T, Maxwell L, Maclean R, Tugwell P (2008) Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 67:260–265CrossRefPubMed
37.
go back to reference Minnock P, Kirwan J, Bresnihan B (2009) Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology 48:1533–1536CrossRefPubMed Minnock P, Kirwan J, Bresnihan B (2009) Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology 48:1533–1536CrossRefPubMed
38.
go back to reference Sokka T, Pincus T (2005) Quantitative joint assessment in rheumatoid arthritis. Clin Exp Rheumatol 23(Suppl 39):S58–S62PubMed Sokka T, Pincus T (2005) Quantitative joint assessment in rheumatoid arthritis. Clin Exp Rheumatol 23(Suppl 39):S58–S62PubMed
39.
go back to reference Campbell RC, Batley M, Hammond A, Ibrahim F, Kingsley G, Scott DL (2012) The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Clin Rheumatol 31:717–722CrossRefPubMed Campbell RC, Batley M, Hammond A, Ibrahim F, Kingsley G, Scott DL (2012) The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Clin Rheumatol 31:717–722CrossRefPubMed
40.
go back to reference Higgins NC, Bailey SJ, LaChapelle DL, Harman K, Hadjistavropoulos T (2015) Coping styles, pain expressiveness, and implicit theories of chronic pain. J Psychol 149:737–750CrossRefPubMed Higgins NC, Bailey SJ, LaChapelle DL, Harman K, Hadjistavropoulos T (2015) Coping styles, pain expressiveness, and implicit theories of chronic pain. J Psychol 149:737–750CrossRefPubMed
Metadata
Title
Fatigue, pain and patient global assessment responses to biological treatment are unpredictable, and poorly inter-connected in individual rheumatoid arthritis patients followed in the daily clinic
Authors
Ole Rintek Madsen
Eva Marie Egsmose
Publication date
01-10-2016
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 10/2016
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3535-y

Other articles of this Issue 10/2016

Rheumatology International 10/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine